Amgen Inc. (AMGN) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $442.36. The rating moved from Neutral to Overbought on August 6, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$442.36
• Last changeMoved from Neutral to Overbought on August 6, 2026
• SectorHealthcare
• IndustryDrug Manufacturers - General

See all overbought Healthcare stocks →

AI analysis

Amgen combines steady, cash-generative core product franchises with scale in biologics R&D and manufacturing. That structural strength and potential for strategic M&A provide a tangible growth runway while also offering defensive qualities in mixed market conditions. Near-term performance will be influenced by quarterly results, pricing dynamics with payers, and any pipeline or partnership news. Key vulnerabilities include payer-driven margin pressure, biosimilar erosion of legacy products, and the risk of clinical/regulatory setbacks. Overall, the company is positioned for modest upside under a stable macro backdrop but remains exposed to execution and policy/pricing risks.

Key factors

• Large, diversified commercial portfolio with several established biologics that generate predictable revenue and strong free cash flow
• Scale in biologics R&D and manufacturing that positions the company to benefit from sustained demand for complex biologic therapies
• Favorable M&A and deal-making environment in biotech/pharma which could enable accretive bolt-on acquisitions or partnerships to accelerate growth
• Defensive characteristics relative to cyclic growth names amid mixed market appetite, supporting downside resilience in volatile sessions
• Near-term catalysts include periodic quarterly results, pipeline readouts, and potential business-development announcements

Risks

• Pricing pressure from payers and Medicare Advantage plan shifts that can compress margins and reduce realized pricing for key products
• Biosimilar competition and patent expirations that could erode sales of legacy biologics over the medium term
• Clinical or regulatory setbacks in late-stage pipeline assets which would reduce forward growth visibility
• Operational/manufacturing disruptions given the complexity of biologics production
• Macro/market volatility or a rising-rate environment that could weigh on valuation multiples for large-cap biopharma

Latest MarketMoodz coverage

• FDA Approves Lumvoa for Thyroid Eye Disease, Puts Tepezza at Risk2026-06-29
• Lilly, Novo Nordisk Lead Next Wave of Obesity Drugs2026-06-13
• Amgen Seeks FDA Hearing to Fight Tavneos Withdrawal2026-06-12
• Amgen Shares Dip as Kissei Urges Caution on Tavneos Use2026-05-18
• Bristol Myers, Hengrui Team Up — China Emerges as R&D Hub2026-05-15

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.